Loading page
Loading page
Loading substance route
Oral administration required. Non-oral routes carry substantial risk of severe adverse effects, including vomiting, dangerous physiological responses, and potentially fatal outcomes.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-21 is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
One documented fatality occurred in 2004 when a 22-year-old consumed an unknown quantity by placing his tongue directly into a vial of powder. He developed hyperthermia (42°C/108°F), experienced a tonic-clonic seizure, entered a coma, and died four days later. Symptoms were consistent with fluoroacetate poisoning. Little is known about the toxicity of 2C-T-21 beyond this incident. Non-oral administration is strongly discouraged as it may cause severe adverse effects or death at high doses.
If the hypothesized fluoroacetate metabolite theory is correct, sub-lethal doses may theoretically cause damage to tissues with high metabolic demands; this remains unconfirmed in human studies and should not be assumed to occur at typical doses.
A tonic-clonic seizure was documented in the one fatal case, which involved an unknown but presumably very high dose. These symptoms are consistent with fluoroacetate poisoning. Seizure risk at typical doses (8-12 mg) is unknown due to limited human data.
2C-T-21 was first synthesized by Alexander Shulgin, representing the final compound in the 2C-T series to be completed. Shulgin and colleagues first described the substance in scientific literature in 1991, with detailed documentation appearing in his book PIHKAL (Phenethylamines I Have Known and
Possession, production, and sale are prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act).
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production, importation for market placement, administration to others, marketing, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalties.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 due to the phenethylamine catch-all clause. Class A drugs carry the most severe penalties, including up to 7 years imprisonment for possession and life imprisonment for supply.
Became a controlled substance under Schedule III of the Controlled Drugs and Substances Act on October 31, 2016.
Regulated as a phenethylamine derivative under Verzeichnis E point 130 of the Betäubungsmittelverzeichnisverordnung. Exemptions exist for legitimate scientific or industrial applications.
Not specifically scheduled under the Controlled Substances Act. However, due to structural similarity to 2C-T-7, possession or sale intended for human consumption may be prosecuted under the Federal Analogue Act as a Schedule I equivalent. In 2004, a chemical supplier was federally indicted for distributing 2C-T-21 as a controlled substance analogue, subsequently pleading guilty in March 2005.
13 sources cited